Takeda Pharmaceutical (TAK) News Today $14.08 +0.22 (+1.55%) Closing price 03:59 PM EasternExtended Trading$14.00 -0.07 (-0.53%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Trump Set To Break WTO Rules With Potential Pharma TariffsFebruary 20 at 9:21 AM | seekingalpha.comPetri Dish: One Boston biotech shuts down, another bags $90MFebruary 20 at 9:21 AM | bizjournals.comHow the owner of Rebelle in Kendall Square traded in beakers for bagelsFebruary 19 at 5:51 PM | bizjournals.comIs Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?February 15, 2025 | insidermonkey.comVan ECK Associates Corp Grows Stock Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)Van ECK Associates Corp grew its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 1.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,210,428 shares of the companyFebruary 15, 2025 | marketbeat.comStrong Q3, Improved Guidance Are Signs Takeda Pharmaceutical May Be UndervaluedJanuary 31, 2025 | seekingalpha.comTakeda announces appointment of Julie Kim as CEOJanuary 31, 2025 | msn.comTakeda Pharmaceutical Company Limited (NYSE:TAK) Sees Significant Decrease in Short InterestTakeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 3,710,000 shares, a drop of 24.4% from the December 31st total of 4,910,000 shares. Based on an average daily volume of 1,710,000 shares, the short-interest ratio is presently 2.2 days.January 31, 2025 | marketbeat.comTakeda Pharmaceutical Company Limited (TAK) Q3 2025 Earnings Call TranscriptJanuary 30, 2025 | seekingalpha.comTakeda Pharmaceutical (NYSE:TAK) Announces Earnings ResultsTakeda Pharmaceutical (NYSE:TAK - Get Free Report) posted its quarterly earnings data on Thursday. The company reported $0.42 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 6.49% and a return on equity of 10.00%.January 30, 2025 | marketbeat.comTakeda Pharmaceutical (NYSE:TAK) Updates FY 2024 Earnings GuidanceTakeda Pharmaceutical (NYSE:TAK) updated its FY 2024 earnings guidance. The company provided EPS guidance of 3.330-3.330 for the period.January 30, 2025 | marketbeat.comTakeda Pharmaceutical (TAK) Projected to Post Quarterly Earnings on ThursdayTakeda Pharmaceutical (NYSE:TAK) will be releasing earnings before the market opens on Thursday, February 6, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=656816)January 30, 2025 | marketbeat.comJulie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026January 30, 2025 | businesswire.comJapan's Takeda says Q3 profit slid 38%, trailing analyst estimatesJanuary 30, 2025 | reuters.comTakeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin GrowthJanuary 30, 2025 | businesswire.comNeurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)January 27, 2025 | prnewswire.comNovo Nordisk (NVO) Gets a Buy from TD CowenJanuary 24, 2025 | markets.businessinsider.comTakeda-backed Ascentage Pharma aims to raise $126 million in US IPOJanuary 24, 2025 | msn.comCrossmark Global Holdings Inc. Purchases 155,795 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)Crossmark Global Holdings Inc. lifted its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 284.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 210,4January 23, 2025 | marketbeat.comTakeda-backed Ascentage Pharma targets $1.75 billion valuation in US IPOJanuary 21, 2025 | reuters.comLegacy Wealth Asset Management LLC Sells 20,779 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)Legacy Wealth Asset Management LLC lessened its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 12.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 140,837 sharJanuary 17, 2025 | marketbeat.comTakeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Clean Yield GroupClean Yield Group trimmed its position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 11.4% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 360,091 shares of the company's stock after sellinJanuary 13, 2025 | marketbeat.comBoston office market starts 2025 with record-high vacancy rateJanuary 9, 2025 | bizjournals.comTakeda Pharmaceutical (NYSE:TAK) Sees Unusually-High Trading Volume - Here's WhyTakeda Pharmaceutical (NYSE:TAK) Sees Unusually-High Trading Volume - Here's What HappenedJanuary 8, 2025 | marketbeat.comONL Therapeutics Appoints Penny Fleck as Chief Development OfficerJanuary 7, 2025 | finance.yahoo.comHUTCHMED to divest 45% equity interest in SHPL for $608mJanuary 2, 2025 | msn.comTakeda Reports Approval Of HYQVIA Injection Set In Japan - Quick FactsDecember 27, 2024 | markets.businessinsider.comTakeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or HypogammaglobulinemiaDecember 27, 2024 | businesswire.comJane Street Group LLC Has $1.73 Million Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)Jane Street Group LLC trimmed its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 91.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 121,830 shares of the company's stock after selling 1,December 26, 2024 | marketbeat.com42,244 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Purchased by Public Employees Retirement System of OhioPublic Employees Retirement System of Ohio bought a new stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund bought 42,244 shares of the company's stock, valued at approximately $601,000. A numberDecember 21, 2024 | marketbeat.comHighTower Advisors LLC Purchases 81,653 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)HighTower Advisors LLC boosted its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 199.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 122,587 shares of the company's stock after purchasinDecember 15, 2024 | marketbeat.comStifel Financial Corp Grows Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)Stifel Financial Corp grew its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 103.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 440,666 shares of the company's stock afDecember 14, 2024 | marketbeat.comKeros Stock Hits Rock Bottom After Pulmonary Hypertension Trial Halt, But Retail Bets On A ReboundDecember 12, 2024 | msn.comKeros Therapeutics: How To Respond To Today's Major Safety Setback And SelloffDecember 12, 2024 | seekingalpha.comJanus Henderson Group PLC Reduces Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)Janus Henderson Group PLC trimmed its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 17.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 256,447 shares of the company's stock after sellDecember 12, 2024 | marketbeat.comJ.P. Morgan Remains a Sell on GlaxoSmithKline (GSK)December 11, 2024 | markets.businessinsider.com67,286 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Purchased by XTX Topco LtdXTX Topco Ltd bought a new position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 67,286 shares of the company's stock, valued at approDecember 11, 2024 | marketbeat.comTakeda Pharmaceutical (TSE:4502) Advances with New Product Update and Strategic Alliances for GrowthDecember 10, 2024 | finance.yahoo.comFmr LLC Buys 286,052 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)Fmr LLC boosted its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 10.9% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,908,918 shares of the company's stock after acquiringDecember 8, 2024 | marketbeat.comTakeda Pharmaceutical: Dividend Yield Is High But Hides Pitfalls Especially For US InvestorsDecember 7, 2024 | seekingalpha.com107,808 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Purchased by Verition Fund Management LLCVerition Fund Management LLC bought a new stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 107,808 shares oDecember 7, 2024 | marketbeat.comTeva Pharma To Divest Teva-Takeda Business Venture In Japan To JKIDecember 5, 2024 | markets.businessinsider.comKeros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: AnalystDecember 3, 2024 | benzinga.comKeros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: AnalystDecember 3, 2024 | benzinga.comTakeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros TherapeuticsDecember 3, 2024 | businesswire.comCerity Partners LLC Buys 61,271 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)Cerity Partners LLC boosted its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 93.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 127,071 shares of the company's stock afDecember 3, 2024 | marketbeat.comTakeda Shows Strong Growth and Raises GuidanceNovember 29, 2024 | markets.businessinsider.comAlloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy PlatformNovember 20, 2024 | businesswire.comAnalysts Offer Insights on Healthcare Companies: Lineage Therap (LCTX), Veeva Systems (VEEV) and Takeda Pharmaceutical Company (TAK)November 19, 2024 | markets.businessinsider.comHalozyme says €2 billion takeover of Evotech would create leader in drug discoveryNovember 19, 2024 | msn.com Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Email Address TAK Media Mentions By Week TAK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TAK News Sentiment▼0.260.60▲Average Medical News Sentiment TAK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TAK Articles This Week▼54▲TAK Articles Average Week Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SNY News Today GSK News Today ARGX News Today BNTX News Today TEVA News Today SMMT News Today GMAB News Today ITCI News Today VTRS News Today MRNA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:TAK) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Company Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TAK Stock Alerts